SEC okays Covaxin phase-3 trials data, 77.8% efficacy
A day ahead of Bharat Biotech’s pre-submission meeting with the World Health Organisation (WHO) for emergency use listing (EUL) for Covaxin, the subject expert committee (SEC) has given its nod to the vaccine’s phase-3 efficacy trials data.
Admin
0
6
A day ahead of Bharat Biotech’s pre-submission meeting with the World Health Organisation (WHO) for emergency use listing (EUL) for Covaxin, the subject expert committee (SEC) has given its nod to the vaccine’s phase-3 efficacy trials data. 
